Study of INBRX-105 in Patients With Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Esophageal Adenocarcinoma
- Gastric Adenocarcinoma
- Head and Neck Squamous Cell Carcinoma
- Melanoma
- Metastatic Solid Tumors
- Non -Small Cell Lung Cancer
- Renal Cell Carcinoma
- Urothelial Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03809624
- Collaborators
- Not Provided
- Investigators
- Study Director: Klaus Wagner, MD, PhD Inhibrx, Inc.